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transplantation as salvage treatment for endocarditis (Duke
criteria) with extensive perivalvular lesions and end-stage heart
failure. The median age was 45 years (range, 24 to 64), and the
aortic valve was affected in all patients. Pathogens were
Staphylococcus aureus (n = 2), Streptococcus pneumoniae (n = 2),
Streptococcus agalactiae (n = 1), or not documented (n = 1). All
patients survived, with no relapse, after a median follow-up of 24.5
months. The 10 patients with heart transplantation for
endocarditis previously reported also survived (median follow-up,
27.5 months). Heart transplantation may be considered as salvage
treatment in selected patients with intractable infective endocarditis.
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mortality of approximately 20%. Extensive cardiac lesions,
including severe regurgitations, paravalvular abscesses, and
ﬁstulae, occur in approximately 20% of aortic IE [1], and require
urgent cardiac surgery. However, valve replacement during the
acute phase of IE is associated with an increased risk of relapses,
paravalvular leaks, or prosthesis dehiscence, which may require
additional cardiac surgery, if still feasible. When valve replace-
ment turns out to be impossible to perform due to extensive
perivalvular lesions and/or end-stage heart failure, heart trans-
plantation (HT)may be the last-resort procedure, although active
infections are considered contraindications to HT [2]. According
to the 2009 European guidelines, cardiac transplantation may be
considered in extreme cases in which repeated operative pro-
cedures have failed to eradicate persistent or recurrent pros-
thetic valve endocarditis (PVE) [3]. Over the last 10 years, we
performed HT as a salvage treatment for six patients with
intractable IE after optimised medical treatment and repeated
valvular surgeries. We report these six cases and a literature
review to better inform colleagues on the beneﬁts and the risks
associated with this last-resort procedure in intractable IE.
Rennes University Hospital is a 1500-bed tertiary care hospital
that serves as a referral centre for IE and HT in western France
(population catchment area, 1 million inhabitants). Patients with
suspected IE are managed by a multidisciplinary team from car-
diac surgery, cardiology, infectious diseases, and microbiology
departments. Data for clinical, microbiological, echocardio-
graphic, therapeutic, and follow-up variables are collected pro-
spectively. All patients who underwent HT for IE were identiﬁed
through a computerised database on HT. Only patients with
deﬁnitive IE (Duke modiﬁed criteria [4]) and >3 months of
follow-up after HT were enrolled. Data were extracted from
medical charts through a standardised questionnaire. All patients
provided informed consent. We searched Medline and Embase
for articles in English published before September 2014, using the
following keywords in various combinations: “heart trans-
plantation”, “endocarditis”, and “salvage treatment”.
Between January 2005 and April 2014, 320 patients under-
went valvular surgery for IE in our institution. Over the same
period, 168 HTs were performed, including 57 of high emer-
gency priority. Among the latter, six male patients with a me-
dian age of 45 years (range, 24 to 64) underwent HT for IE
refractory to medical treatment and repeated valvular sur-
geries. In agreement with guidelines for selection of candidates
for HT, patients had no comorbidity associated with reduced
life expectancy over the next 5 years. HT was considered asClin Microbiol Infect 2015; 21: 371.e1–371.e4
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.11.027
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371.e2 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIsalvage treatment because of extensive perivalvular lesions
associated with end-stage heart failure. Patient characteristics
are presented in Table 1. Initial surgery consisted of valve
replacement with debridement of all infected tissues, and
reconstruction using felt or equine pericardium in all patients.
Aortic annular abscess was found in all patients at the time of
the ﬁrst surgery, with severe destruction and vegetations of the
valvular apparatus. Postoperative follow-up echocardiography
showed early recurrence of infection with prosthesis dehis-
cence and extensive destruction of cardiac structures for all
patients, which led to one or two additional surgeries. The
indication for emergency HT was considered by dedicated
multidisciplinary staff and validated by a national board of HT
experts. By that time, all patients presented with 1) major
valvular and perivalvular lesions, 2) congestive heart failure, and
3) three consecutive sets of sterile blood cultures after 5 days
incubation. All patients underwent urgent orthotopic HT. The
median time between ﬁrst cardiac surgery for IE and HT was 69
days. All samples collected during surgery remained sterile.
Antibiotics were used for 2 weeks after HT for all patients
except for patient 2, who received 6 weeks of cefotaxime
posttransplantation because of Escherichia coli mediastinitis. All
patients survived with a functional graft and no IE relapse after a
median follow-up of 24.5 months (range, 5 months to 9 years).
One patient experienced severe HT-related complications with
two episodes of graft rejection and constrictive pericarditis.
Ten additional observations of HT as salvage treatment of
intractable IE have been previously reported (Table 2) [5–14].
Patients weremostly male (n = 7), with amedian age of 38.5 years
(range, 17 to 70). Criteria for HT were in agreement with ours
(intractable heart lesions, infection controlled, no severe co-
morbidity). Pathogens were mostly Gram-positive cocci,
although unusual pathogens also were implicated (Coxiella bur-
nettii, Brucella melitensis, Mycoplasma hominis). All patients sur-
vived, with a median follow-up of 27.5 months (range, 3 months
to 18 years), despite severe complications that occurred in three
patients (including onewho required a second HT for IE relapse).
The main ﬁndings of this case series and systematic review of
salvage HT for intractable IE are the following: 1) Despite major
achievements in HT techniques over the last decades, this
procedure is still rarely performed in patients with IE (3% of
indications for HT in our institution; only 10 cases reported to
date). 2) Thus far, the outcomes seem favourable in most cases,
with post-HT follow-up extending to 18 years, 100% survival
rate, and only one (6%) relapse. These results were obtained in
highly selected patients with intractable IE, no major comor-
bidity, and repeated sets of sterile blood cultures before HT.
These patients presented with multiple risk factors for severe
complications, including S. aureus IE, prosthetic valve, severe
aortic regurgitation, periannular abscesses, intracardiac ﬁstulae,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 371.e1–371.e4
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inand heart failure. In this context, the 100% survival rate with no
relapse in our case series must be underlined.
To the best of our knowledge, this is the ﬁrst case series of
consecutive patients treated with HT for intractable IE. This
series is informative in several aspects. 1) It increases the
number of patients reported to date, which consolidates pre-
vious ﬁndings. 2) We reported all patients who underwent HT
for intractable IE in our institution, hence limiting publication
bias. Indeed, single case reports are more likely to be submitted
and accepted for publication when the outcome is favourable,
which limits the interpretation of cumulative ﬁndings extracted
from single-case reports. Our work has limitations, including
sample size and single-centre design. Hence, our ﬁndings may
not be extrapolated to other settings. However, these case
series and literature review suggest that in selected patients, HT
should be considered as salvage treatment in intractable IE
when conventional valve surgery is not feasible due to extensive
perivalvular lesions or end-stage heart failure.
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